Form 4: Voyager Therapeutics Director Receives Stock Options
Statement of Changes in Beneficial Ownership
Voyager Therapeutics, Inc. reports that Director James A. Geraghty was granted stock options under the company's 2025 Stock Incentive Plan.
Summary
- Director James A. Geraghty of Voyager Therapeutics, Inc. was granted 30,000 stock options with an exercise price of $3.43.
- These options were issued under the company's 2025 Stock Incentive Plan as part of the director compensation policy.
- The options vest one year from the grant date or on the date of the next annual stockholder meeting, provided the director continues to serve.
- The earliest transaction date associated with this filing is June 9, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation in the form of stock options, without providing new financial or strategic information.
Positives
- Director compensation through stock options aligns management incentives with shareholder value.
- The grant of options suggests confidence in the company's future performance and stock price appreciation.
Risks
- The value of the stock options is subject to market fluctuations and the company's future performance.
- Vesting is contingent on continued service, meaning the director could forfeit unvested options if they leave the company.
Future Outlook
The filing itself does not contain forward-looking statements or guidance. The stock options granted imply a positive outlook on the company's future stock performance.
Industry Context
StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive compensation with long-term company performance and shareholder interests.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | James A. Geraghty has granted a power of attorney to specific individuals to act on his behalf for SEC filings, including Forms 3, 4, 5, Schedules 13D/13G, and Forms 144. | May 29, 2026 | Streamlines the filing process for insider transactions and reporting requirements, ensuring compliance. |
Related Party Transactions
- The grant of 30,000 stock options to Director James A. Geraghty is a related party transaction, issued under the company's director compensation policy.
Stakeholder Impact
- Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes directors to act in the best interest of shareholders.
- Employees: The company's use of stock options for director compensation may indicate a broader equity-based compensation strategy.
Next Steps
- The director must continue to serve the company for the stock options to vest.
- The stock options will expire on June 9, 2036, if not exercised.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Earliest transaction date and grant date of stock options. |
| 06/11/2026 | Date of signature for the filing. |
| 06/09/2036 | Expiration date of the stock options. |
Keywords
Voyager Therapeutics, VYGR, Form 4, Stock Options, Director Compensation, SEC Filing, Insider Trading, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.